UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of ~~March~~April, 2023

Commission File Number: 001-39365

Amryt Pharma PLC

(Translation of registrant’s name into English)

Dept 920a 196 High Road, Wood Green,

London, United Kingdom, N22 8HH

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

~~Results~~Sanction of ~~Amryt~~Scheme ~~Shareholder~~of ~~Meetings.~~Arrangement

OnAt ~~March~~a ~~22,~~hearing ~~2023, Amryt Pharma Plc (the “Company”)~~ held aon ~~meeting~~March of31, ~~shareholders~~2023, ~~convened with~~ the ~~permission of the~~ High Court of Justice of England and Wales (the “Court” ~~and, such meeting, the “Court Meeting”~~) ~~and~~sanctioned ~~a general meeting of shareholders (~~the “General Meeting” and together with the Court Meeting, the “Shareholder Meetings”), in each case in connection with the previously announced transaction whereby Chiesi Farmaceutici S.p.A., an Italian società per azioni (“Chiesi”), will acquire the entire issued and to be issued share capital of the Company (the “Transaction”) pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Scheme of Arrangement”). ~~The~~providing ~~Company~~for ~~published~~the aproposed ~~scheme~~acquisition ~~circular regarding~~ (the “Transaction”) onof ~~February~~Amryt ~~16,~~Pharma ~~2023~~Plc (the “~~Scheme Circular~~Company”) by Chiesi Farmaceutici S.p.A., an Italian società per azioni.

AsThe ofCompany ~~6:00~~published ~~p.m.~~a ~~(London~~scheme ~~time)~~circular onregarding ~~March 20, 2023,~~ the ~~voting~~Transaction ~~record~~on ~~time~~February ~~for~~16, ~~the~~2023 ~~Shareholder Meetings~~ (the “~~Voting~~Scheme ~~Record Time~~Circular”)~~, the Company’s issued share capital consisted of 320,669,417 ordinary shares carrying one vote each~~. ~~244,113,996~~The ~~ordinary~~parties ~~shares~~expect of the ~~Company~~closing ~~were voted by shareholders present in person or by proxy at the Court Meeting. 243,891,202 ordinary shares~~ of the ~~Company~~Transaction ~~were~~to ~~voted~~take byplace ~~shareholders present~~ in ~~person~~mid-April ~~or by proxy at the General Meeting~~ 2023. ~~All votes at both the Court Meeting and the General Meeting were conducted on a poll.~~

~~The~~Announcement ~~final results~~ of ~~voting~~Sanction ~~on each~~ of ~~the~~Scheme ~~items submitted to a vote~~ of ~~the~~Arrangement ~~Company’s~~Press ~~shareholders at the Court Meeting and the General Meeting are set forth below.~~Release

~~The~~On ~~consummation~~April of3, 2023, the ~~Transaction~~Company ~~remains~~issued ~~subject~~a topress ~~closing~~release ~~conditions,~~announcing ~~including~~ the sanction of the Scheme of Arrangement by the Court, which also discloses that the parties expect the Transaction to close in mid-April 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

~~Court~~ADDITIONAL ~~Meeting~~INFORMATION AND WHERE TO FIND IT

This Report of Foreign Private Issuer on Form 6-K is not a substitute for the Scheme ~~Proposal:~~Circular or any other document that may be filed or furnished by the Company with the SEC. Investors and security holders are urged to ~~approve~~carefully read the entire Scheme Circular (which includes an explanatory statement in respect of ~~Arrangement~~the Scheme in accordance with the requirements of the U.K. Companies Act 2006) and other relevant documents as and when they become available because they will contain important information.

~~The~~You ~~Company~~may obtain copies of all documents filed with or furnished to the SEC regarding this transaction, free of charge, at the SEC’s website (www.sec.gov). In addition, investors and shareholders ~~approved~~will be able to obtain free copies of the Scheme ~~Proposal~~Circular and other documents filed with or furnished to the ~~following~~SEC ~~results~~by the Company on the Company’s Investor Relations website (https://amrytpharma.com/investors/) or by writing to the Company, Corporate Secretary, Dept 920a 196 High Road, Wood Green, London, United Kingdom, N22 8HH (for documents filed with or furnished to the SEC by the Company).

FOR		% OF SCHEME SHARES FOR		AGAINST		% OF SCHEME SHARES AGAINST
243,833,323		99.89%		280,673		0.11%

Of the 112 record shareholders voting on the proposal, 107 record shareholders or 95.54% of those voting voted in favor of the proposal (constituting a majority in number of record voters voting in person or by proxy who together held in excess of 75% in value of the shares represented) and 5 record shareholders or 4.46% of those voting voted against the proposal.

General Meeting

Scheme Implementation Proposal: to (i) authorize the Company’s Board of Directors to take all action necessary or appropriate for carrying the Scheme of Arrangement into effect and (ii) make certain amendments to the articles of association of the Company in order to facilitate the Transaction, including provisions to ensure that any of the Company’s ordinary shares that are issued at or after the Voting Record Time will either be subject to the terms of the Scheme of Arrangement or will be acquired by Chiesi on the same terms as under the Scheme of Arrangement.

The Company’s shareholders approved the Scheme Implementation Proposal with the following results:

FOR		% OF SCHEME SHARES FOR		AGAINST		% OF SCHEME SHARES AGAINST		WITHHELD
243,827,890		99.97%		63,312		0.03%		14,990

Further information regarding each of the foregoing proposals is set forth in the Scheme Circular.

Results Announcement Press Release

On March 22, 2023, the Company issued a press release announcing the results of the Shareholder Meetings, which also discloses that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in respect of the Transaction has expired. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Amryt Pharma Plc
	By:	/s/ Rory Nealon
	Name:	Rory Nealon
	Title:	Chief Financial Officer
Date: March 22, 2023
Date: April 3, 2023

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release of the Company, dated ~~March~~April 223, 2023.

Filing Compare · Amryt Pharma plc